Literature DB >> 24155638

Recurrent nasopharyngeal carcinoma: a clinical dilemma and challenge.

Tao Xu1, J Tang, M Gu, L Liu, W Wei, H Yang.   

Abstract

Recurrent nasopharyngeal carcinoma, which represents a small proportion of head-and-neck cancers, has a unique set of patho-clinical characteristics. The management of recurrent nasopharyngeal carcinoma remains a challenging clinical problem. Traditional treatments offer limited local control and survival benefits; more seriously, they frequently induce severe late complications. Recently, novel treatment techniques and strategies-including precision radiotherapy, endoscopic surgery or transoral robotic resection, third-generation chemotherapy regimens, and targeted therapies and immunotherapy-have provided new hope for patients with recurrent nasopharyngeal carcinoma. Some of these patients can potentially be cured with modern treatments. However, a lack of adequate evidence makes it difficult for clinicians to apply these powerful techniques and strategies. Individualized management guidelines, full evaluation of quality of life in these patients, and a further understanding of the mechanisms underlying recurrence are future directions for research into recurrent nasopharyngeal carcinoma.

Entities:  

Keywords:  Nasopharyngeal carcinoma; biotherapy; chemotherapy; radiotherapy; recurrence; surgery

Year:  2013        PMID: 24155638      PMCID: PMC3805410          DOI: 10.3747/co.20.1456

Source DB:  PubMed          Journal:  Curr Oncol        ISSN: 1198-0052            Impact factor:   3.677


  101 in total

1.  Re-irradiation of nasopharyngeal carcinoma with intensity-modulated radiotherapy.

Authors:  Daniel T T Chua; Jonathan S T Sham; Lucullus H T Leung; Gordon K H Au
Journal:  Radiother Oncol       Date:  2005-11-08       Impact factor: 6.280

2.  Combined transnasal endoscopic and transoral robotic resection of recurrent nasopharyngeal carcinoma.

Authors:  Raymond King Yin Tsang; Wai Kuen Ho; William I Wei
Journal:  Head Neck       Date:  2011-03-17       Impact factor: 3.147

3.  Reirradiation for recurrent nasopharyngeal carcinoma: factors affecting the therapeutic ratio and ways for improvement.

Authors:  A W Lee; W Foo; S C Law; Y F Poon; W M Sze; S K O; S Y Tung; W H Lau
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-04-01       Impact factor: 7.038

4.  Nasopharyngectomy for recurrent nasopharyngeal cancer: a 2- to 17-year follow-up.

Authors:  Willard E Fee; Melinda S Moir; Eun Chang Choi; Don Goffinet
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2002-03

5.  A phase II study of pemetrexed combined with cisplatin in patients with recurrent or metastatic nanopharyngeal carcinoma.

Authors:  T K Yau; T Shum; A W M Lee; M W Yeung; W T Ng; L Chan
Journal:  Oral Oncol       Date:  2011-12-27       Impact factor: 5.337

6.  Dose escalation of three-dimensional conformal radiotherapy for locally recurrent nasopharyngeal carcinoma: a prospective randomised study.

Authors:  J C Li; C S Hu; G L Jiang; N A Mayr; J Z Wang; X Y He; Y Ru Wu
Journal:  Clin Oncol (R Coll Radiol)       Date:  2006-05       Impact factor: 4.126

Review 7.  How successful is high-dose (> or = 60 Gy) reirradiation using mainly external beams in salvaging local failures of nasopharyngeal carcinoma?

Authors:  P M Teo; W H Kwan; A T Chan; W Y Lee; W W King; C O Mok
Journal:  Int J Radiat Oncol Biol Phys       Date:  1998-03-01       Impact factor: 7.038

8.  Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck.

Authors:  Sharon A Spencer; Jonathan Harris; Richard H Wheeler; Mitchell Machtay; Christopher Schultz; William Spanos; Marvin Rotman; Ruby Meredith; Kie-Kian Ang
Journal:  Head Neck       Date:  2008-03       Impact factor: 3.147

9.  Nasopharyngectomy for recurrent nasopharyngeal carcinoma: a review of 53 patients and prognostic factors.

Authors:  Sheng-Po Hao; Ngan-Ming Tsang; Kai-Ping Chang; Yung-Shin Hsu; Chin-Kuo Chen; Ku-Hao Fang
Journal:  Acta Otolaryngol       Date:  2008-04       Impact factor: 1.494

10.  Linear accelerator-based stereotactic radiosurgery for limited, locally persistent, and recurrent nasopharyngeal carcinoma: efficacy and complications.

Authors:  Daniel T T Chua; Jonathan S T Sham; Philip W K Kwong; Kwan-Ngai Hung; Lucullus H T Leung
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-05-01       Impact factor: 7.038

View more
  41 in total

Review 1.  The molecular march of primary and recurrent nasopharyngeal carcinoma.

Authors:  Nicholas J Campion; Munira Ally; Bernhard J Jank; Jahangir Ahmed; Ghassan Alusi
Journal:  Oncogene       Date:  2021-01-21       Impact factor: 9.867

2.  Value of 18F-FDG heterogeneity for discerning metastatic from benign lymph nodes in nasopharyngeal carcinoma patients with suspected recurrence.

Authors:  Seung Hwan Moon; Young Seok Cho; Young-Ik Son; Yong Chan Ahn; Myung-Ju Ahn; Joon Young Choi; Byung-Tae Kim; Kyung-Han Lee
Journal:  Br J Radiol       Date:  2016-09-21       Impact factor: 3.039

3.  Non-Coding RNA Pvt1 Promotes Cancer Stem Cell-Like Traits in Nasopharyngeal Cancer via Inhibiting miR-1207.

Authors:  Meng Cui; Yu Chang; Qi-Gen Fang; Wei Du; Jun-Fu Wu; Ji-Heng Wang; Shan-Ting Liu; Su-Xia Luo
Journal:  Pathol Oncol Res       Date:  2018-08-23       Impact factor: 3.201

4.  Phase I Study of CC-486 Alone and in Combination with Carboplatin or nab-Paclitaxel in Patients with Relapsed or Refractory Solid Tumors.

Authors:  Daniel D Von Hoff; Drew W Rasco; Elisabeth I Heath; Pamela N Munster; Jan H M Schellens; Nicolas Isambert; Christophe Le Tourneau; Bert O'Neil; Ron H J Mathijssen; Jose A Lopez-Martin; W Jeff Edenfield; Miguel Martin; Patricia M LoRusso; Gordon L Bray; Jorge DiMartino; Aaron Nguyen; Kejian Liu; Eric Laille; Johanna C Bendell
Journal:  Clin Cancer Res       Date:  2018-05-15       Impact factor: 12.531

5.  Molecular landscape and subtype-specific therapeutic response of nasopharyngeal carcinoma revealed by integrative pharmacogenomics.

Authors:  Ren-Bo Ding; Ping Chen; Barani Kumar Rajendran; Xueying Lyu; Haitao Wang; Jiaolin Bao; Jianming Zeng; Wenhui Hao; Heng Sun; Ada Hang-Heng Wong; Monica Vishnu Valecha; Eun Ju Yang; Sek Man Su; Tak Kan Choi; Shuiming Liu; Kin Iong Chan; Ling-Lin Yang; Jingbo Wu; Kai Miao; Qiang Chen; Joong Sup Shim; Xiaoling Xu; Chu-Xia Deng
Journal:  Nat Commun       Date:  2021-05-24       Impact factor: 14.919

6.  Molecular markers to assess short-term disease local recurrence in nasopharyngeal carcinoma.

Authors:  Tao Xu; Bojin Su; Chunhua Wang; Sumei Wang; Hecheng Huang; Yunbao Pan; Donghui Wang; Weihong Wei; François X Claret; Huiling Yang
Journal:  Oncol Rep       Date:  2015-01-20       Impact factor: 3.906

7.  In vivo molecular imaging and radionuclide (131I) therapy of human nasopharyngeal carcinoma cells transfected with a lentivirus expressing sodium iodide symporter.

Authors:  Shuo Shi; Min Zhang; Rui Guo; Ying Miao; Jiajia Hu; Yun Xi; Biao Li
Journal:  PLoS One       Date:  2015-01-26       Impact factor: 3.240

8.  Prognostic value of the primary lesion apparent diffusion coefficient (ADC) in nasopharyngeal carcinoma: a retrospective study of 541 cases.

Authors:  Yuan Zhang; Xu Liu; Yun Zhang; Wen-Fei Li; Lei Chen; Yan-Ping Mao; Jing-Xian Shen; Fan Zhang; Hao Peng; Qing Liu; Ying Sun; Jun Ma
Journal:  Sci Rep       Date:  2015-07-17       Impact factor: 4.379

9.  An analysis of brachytherapy with computed tomography-guided permanent implantation of Iodine-125 seeds for recurrent nonkeratin nasopharyngeal carcinoma.

Authors:  Xinying Shen; Yong Li; Yanfang Zhang; Jian Kong; Yanhao Li
Journal:  Onco Targets Ther       Date:  2015-05-02       Impact factor: 4.147

10.  lncRNA MIAT/HMGB1 Axis Is Involved in Cisplatin Resistance via Regulating IL6-Mediated Activation of the JAK2/STAT3 Pathway in Nasopharyngeal Carcinoma.

Authors:  Xuewei Zhu; Li Liu; Yang Wang; Jianan Cong; Zhang Lin; Yongsen Wang; Qi Liu; Leiming Wang; Ben Yang; Tao Li
Journal:  Front Oncol       Date:  2021-05-20       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.